Personal care treatments

PharmaCyte Biotech to Participate in the 15th International Conference on Advanced Technologies and Diabetes Treatments

PharmaCyte Biotech, Inc. PMCBa biotechnology company specializing in the development of cellular therapies for cancer and diabetes using its live cell encapsulation technology, Cell-in-a-Box®, today announced that the leadership team will attend the 15th International Conference on Advanced Diabetes Technologies and Treatments (ATTD) to be held April 27-30, 2022 in Barcelona, ​​Spain. ATTD is a scientific conference that was established in 2008. Conference meetings have become the world’s most renowned forum for showcasing developments in new diabetes technologies and treatments.

PharmaCyte CEO Kenneth L. Waggoner said, “This annual conference is where clinicians, diabetes care providers, researchers, industry leaders and investors come together to share knowledge. and develop collaborations. As we continue to expand our product portfolio, developing a treatment for type 1 diabetes and insulin-dependent type 2 diabetes that can essentially serve as an “artificial pancreas” is of vital importance to PharmaCyte. Our treatment based on live cell encapsulation offers real hope for future development in the field of diabetes.

Major topics covered at the conference include Decision Support Systems, Data-Driven Decision Support Systems and Artificial Intelligence, Closed-Loop Systems and Algorithms, Artificial Pancreas, Pumps glucose sensors, implantable pumps and sensors, new insulin analogues and new insulin delivery systems. , devices focused on the prevention of diabetes, IT in the service of medicine; telemedicine, software and other technologies, advanced medical technologies for use in hospitals and more.

In addition to attending presentations and discussions by leading professionals in the field, PharmaCyte’s leadership team will meet with members of its International Diabetes Consortium to launch its new diabetes initiatives.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced, inoperable pancreatic cancer, we encourage you to watch the company’s documentary video with medical animations on: https://www.PharmaCyte.com/Cancer

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing cell therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®This technology is used as a platform on which therapies for several types of cancer and diabetes are developed.

PharmaCyte’s cancer therapy encapsulates genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-fighting” form. For pancreatic cancer, these encapsulated cells are implanted into the blood supply to the patient’s tumor as close to the tumor site as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. Ifosfamide is transported through the circulatory system to where the encapsulated cells have been implanted. When ifosfamide passes through the pores of the capsules, the living cells inside act like a “bio-artificial liver” and activate the chemotherapy drug at the cancer site. This “targeted chemotherapy” has been shown to be effective and safe to use in previous clinical trials and we believe has little or no treatment-related side effects.

PharmaCyte’s therapy for type 1 diabetes and insulin-dependent type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to blood sugar levels in the human body. Cell line encapsulation will be done using the Cell-in-a-Box® Technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a “bio-artificial pancreas” for the purpose of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. All statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. . Factors that could affect our actual results include our ability to raise the capital necessary to fund our operations and secure partners to complement our capabilities and resources, our ability to satisfactorily resolve issues raised by the FDA in order to have a clinical grasp on our deleted INDs, as well as other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the United States Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise any forward-looking statements, except as required by law, whether as a result of new information, future events or otherwise.

For more information about PharmaCyte Biotech, please visit www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.